SCHEMBL302885

SCHEMBL302885

CCC(Br)CCCCCCCCCBr

nearest known ligand 0.32

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
LCK P06239 1/20 0.32
PPARD Q03181 1/20 0.32
ZDHHC20 Q5W0Z9 1/20 0.32
ZDHHC2 Q9UIJ5 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27228253 1.00 LCK (0.32) LCKPPARDZDHHC20ZDHHC2
SCHEMBL27908468 1.00 LCK (0.32) LCKPPARDZDHHC20ZDHHC2
SCHEMBL28070612 1.00 LCK (0.32) LCKPPARDZDHHC20ZDHHC2
SCHEMBL15329517 1.00 LCK (0.32) LCKPPARDZDHHC20ZDHHC2
SCHEMBL8010264 1.00 LCK (0.32) LCKPPARDZDHHC20ZDHHC2
SCHEMBL3666628 0.97
SCHEMBL29055256 0.93 LCK (0.42) LCKPPARDZDHHC20ZDHHC2
SCHEMBL647281 0.89
SCHEMBL19439531 0.89 LCK (0.37) LCKPPARDZDHHC20ZDHHC2
SCHEMBL8554463 0.82 DNM1 (0.40) LCKPPARDZDHHC20ZDHHC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114957900-B Magnetic porous polyion liquid material, preparation method and device thereof 国家纳米科学中心 2024-07-05 CN disclosed
US-20230056135-A1 MONOMER AND MULTIMERIC ANTI-HBV AGENTS EMORY UNIVERSITY (US) 2023-02-23 US disclosed
CN-114957900-A Magnetic porous polyion liquid material, preparation method and device thereof 国家纳米科学中心 2022-08-30 CN disclosed
CN-113166115-A Monomeric and multimeric anti-HBV agents 埃默里大学 2021-07-23 CN disclosed
CN-107285335-A A kind of preparation method of the preparation method of template and load Ti MFI molecular sieves 广东工业大学 2017-10-24 CN disclosed
CN-104402020-A Micro-mesoporous beta molecular sieve and preparation method and application thereof UNIV SOUTH CHINA TECH 2015-03-11 CN disclosed
US-20140142178-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA KAREUS THERAPEUTICS, SA (CH) 2014-05-22 US disclosed
US-20140121267-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA KAREUS THERAPEUTICS, SA (CH) 2014-05-01 US disclosed
US-8623897-B2 Methods and compositions for treatment of diabetes and dyslipidemia KAREUS THERAPEUTICS, SA (CH) 2014-01-07 US disclosed
CN-103327974-A Methods and compositions for treating diabetes and dyslipidemia KAREUS THERAPEUTICS SA 2013-09-25 CN disclosed
US-7468441-B2 1-imidazolymethyl-substituted-2-naphtols and their use as accelerators for low-temperature curing HUNSTMAN ADVANCED MATERIALS AMERICAS INC. (US) 2008-12-23 US disclosed
US-20060211845-A1 1-Imidazolymethyl -substituted -2-naphtols and their use as accelerators for low - temperature curing HUNTSMAN ADVANCED MATERIALS AMERICAS INC. (US) 2006-09-21 US disclosed
EP-1613604-B1 1-IMIDAZOLYLMETHYL-SUBSTITUTED-2-NAPHTOLS AND THEIR USE AS ACCELERATORS FOR LOW-TEMPERATURE CURING HUNTSMAN ADV MAT SWITZERLAND (CH) 2006-07-05 EP disclosed
EP-1613604-A1 1-IMIDAZOLYLMETHYL-SUBSTITUTED-2-NAPHTOLS AND THEIR USE AS ACCELERATORS FOR LOW-TEMPERATURE CURING Huntsman Advanced Materials (Switzerland) GmbH (CH) 2006-01-11 EP disclosed
WO-2004092141-A1 1-IMIDAZOLYMETHYL-SUBSTITUTED-2-NAPHTOLS AND THEIR USE AS ACCELERATORS FOR LOW-TEMPERATURE CURING HUNTSMAN ADVANCED MATERIALS (SWITZERLAND) GMBH (CH) 2004-10-28 WO disclosed
CN-1105558-C 2,2-dichloroalkane carboxylic acids, process for preparing the same, medicament containing the same and use for treating insulin resistance ROCHE DIAGNOSTICS GMBH (DE) 2003-04-16 CN disclosed
US-5968982-A TREATMENT OF DIABETES ROCHE DIAGNOSTICS GMBH (DE) 1999-10-19 US disclosed
US-5871670-A Electroconductive composition CIBA SPECIALTY CHEMICALS CORPORATION (US) 1999-02-16 US disclosed
CN-1171050-A 2, 2-Dichloroalkanecarboxylic acids, method for the production thereof, medicaments containing the same and use thereof for the treatment of insulin resistance BOEHRINGER MANNHEIM GMBH (DE) 1998-01-21 CN disclosed
EP-0377175-A2 Pattern forming composition and process for forming pattern using the same HITACHI, LTD. (JP) 1990-07-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211845-A1 1-Imidazolymethyl -substituted -2-naphtols and their use as accelerators for low - temperature curing NOP2, LMNA, RPL39 LCK 4824/4885PPARD 4695/4885ZDHHC20 4673/4885
US-20230056135-A1 MONOMER AND MULTIMERIC ANTI-HBV AGENTS HAVCR2, HMBS, HDGF LCK 4017/4885PPARD 1519/4885ZDHHC20 4148/4885
US-20140121267-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA GPR119, FFAR1, INSR LCK 1823/4885PPARD 273/4885ZDHHC20 1066/4885
US-20140142178-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA DHCR7, INSR, GPR119 LCK 1152/4885PPARD 324/4885ZDHHC20 1178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.